Trials / Unknown
UnknownNCT03480256
Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer
Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to assess the safety and tolerability of SHR6390 combined with pyrotinib in the patients with Her-2 positive advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6390 | SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway.Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic gastric cancer |
Timeline
- Start date
- 2018-07-27
- Primary completion
- 2019-11-01
- Completion
- 2020-08-01
- First posted
- 2018-03-29
- Last updated
- 2019-03-14
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03480256. Inclusion in this directory is not an endorsement.